Business Context and Reporting Period
This Form 8-K Current Report was filed by Oruka Therapeutics, Inc. (Nasdaq: ORKA) on July 1, 2025. The filing reports the appointment of a new Chief Operating Officer and details the associated compensatory arrangements.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on executive compensation and personnel changes.
Material Changes
On July 1, 2025, Laura Sandler was appointed as Chief Operating Officer, promoting her from her previous role as Senior Vice President of Operations. This appointment includes a new letter agreement outlining specific compensation terms.
Management Commentary and Compensation Details
- Base Salary: $460,000 annualized.
- Target Bonus: 40% of annual base salary (discretionary).
- Equity Grant: Stock option for 25,000 shares. Vesting schedule includes 25% on the first anniversary, followed by 36 equal monthly installments.
- Severance (Standard): 12 months of base salary plus 12 months of health coverage upon termination without cause or resignation with good reason.
- Severance (Change in Control): If termination occurs within 3 months before or 12 months after a change in control, the package includes 1.0x the sum of base salary and target bonus, 12 months of health coverage, and full acceleration of all equity awards.
- Death/Disability: Full acceleration of equity awards.
Investor Verification Checklist
- Verify the full text of the Offer Letter filed as Exhibit 10.1 for complete employment terms.
- Confirm the impact of the 25,000 share option grant on total shareholder dilution.
- Review the company's cash position to assess the ability to fund the new executive compensation package and potential severance obligations.
- Monitor future filings for any changes in the company's operational strategy under the new COO leadership.